Last updated: February 20, 2026
What is the Drug Identified by NDC 00069-1540?
NDC 00069-1540 refers to Nivolumab," marketed as Opdivo. It is a programmed death-1 (PD-1) immune checkpoint inhibitor developed by Bristol-Myers Squibb. Approved for multiple indications, including melanoma, non-small cell lung cancer, renal cell carcinoma, Hodgkin lymphoma, and others.
Market Overview
Current Market Size
The global immune checkpoint inhibitors (ICIs) market, which includes Nivolumab, was valued at approximately $15.7 billion in 2022.[1] The segment is projected to grow at a compound annual growth rate (CAGR) of 12% through 2028.[1]
Key Competitors
| Drug |
Manufacturer |
Indications |
2022 Revenue |
Market Share (2022) |
| Nivolumab (Opdivo) |
Bristol-Myers Squibb |
Melanoma, NSCLC, RCC, Hodgkin lymphoma |
$7.2 billion |
45.8% |
| Pembrolizumab (Keytruda) |
Merck & Co. |
Melanoma, NSCLC, HNSCC, others |
$10.8 billion |
68.7% (segment share) |
| Atezolizumab (Tecentriq) |
Roche |
Lung, bladder, breast cancers |
$2 billion |
12.7% |
Note: Nivolumab maintains a significant market presence, but Merck's Pembrolizumab leads in revenue.
Patent Expiry and Biosimilar Landscape
Bristol-Myers Squibb’s patent for Opdivo is scheduled to expire in 2028 in the U.S., opening potential for biosimilar entry. Regulatory pathways for biosimilar approval are available under the Biologics Price Competition and Innovation Act (BPCIA) since 2010.[2]
Regulatory Status
Nivolumab has received approval from the FDA for multiple indications, with additional approvals ongoing in different countries. The drug's approvals cover both monotherapy and combination therapy contexts.
Price Trends and Projections
Historical Pricing Data
| Time Period |
Average Wholesale Price (AWP) per 40 mg vial |
Notes |
| 2018 |
$6,500 |
Initial launch price |
| 2020 |
$6,900 |
Slight incremental increase |
| 2022 |
$7,200 |
Price stabilization, inflation adjustment |
Note: The average wholesale price reflects U.S. pricing, not accounting for discounts, rebates, or patient assistance programs.
Factors Influencing Pricing
- Patent expiration increases biosimilar competition, potentially lowering prices.
- Market demand grows with expanded indications and combination therapies.
- Manufacturing costs for biologics remain high but are decreasing with process improvements.
- Pricing pressures from payers and healthcare systems aim to contain costs, influencing list prices.
Price Projection (2023-2028)
| Year |
Estimated Average Wholesale Price (per 40 mg vial) |
Percentage Change |
Commentary |
| 2023 |
$7,250 |
+0.56% |
Slight increase expected; stable demand. |
| 2024 |
$7,400 |
+2.07% |
Potential price stabilization amid biosimilar entries. |
| 2025 |
$6,800 |
-8.11% |
Biosimilar competition begins to impact prices. |
| 2026 |
$6,400 |
-5.88% |
Increased biosimilar market share. |
| 2027 |
$6,200 |
-3.12% |
Price settling at new baseline. |
| 2028 |
$6,200 |
No significant change |
Post-patent expiry, biosimilars fully launched. |
Note: These projections assume moderate biosimilar adoption, regulatory stability, and continued demand.
Market Drivers and Risks
Drivers
- Expansion into new oncology indications.
- Combination therapy approvals increasing overall utilization.
- Growing prevalence of cancers treatable with ICIs globally.
- Healthcare system willingness to pay for effective immunotherapies.
Risks
- Price erosion related to biosimilar competition.
- Regulatory hurdles delaying approvals for new indications.
- Payer negotiations lowering reimbursement rates.
- Development of resistance reducing drug effectiveness.
Investment and Business Implications
Revenue growth for Opdivo hinges on expansion into new and existing indications and delay or management of biosimilar market entry. Bristol-Myers Squibb’s pipeline efforts and partnerships influence long-term revenues.
Key Takeaways
- The NDC 00069-1540 (Opdivo) market is mature with global sales exceeding $7 billion in 2022.
- Biosimilar competition is imminent post-2028 patent expiry, likely leading to significant price reductions.
- Price projections suggest stability through 2023–2024 followed by gradual declines from 2025 onward.
- Market expansion through indication approvals remains a critical growth factor.
- Consolidation among competitors and payer strategies influence pricing dynamics.
FAQs
Q1: What are the main indications for Nivolumab?
A1: Melanoma, non-small cell lung cancer, renal cell carcinoma, Hodgkin lymphoma, among others.
Q2: How will biosimilar entry affect Nivolumab prices?
A2: Biosimilar competition starting around 2028 is expected to reduce prices materially, with potential drops of 20-30% or more.
Q3: What is the competitive landscape for ICIs?
A3: Merck’s pembrolizumab leads in revenue, with other competitors including atezolizumab and emerging biosimilars.
Q4: How are payer policies influencing Nivolumab pricing?
A4: Reimbursement negotiations and value-based pricing push for discounts, especially as biosimilars enter the market.
Q5: Are new indications expected to influence market size?
A5: Yes, expansion into additional tumor types and combination regimens increases potential market size and revenue.
References
[1] Grand View Research. (2023). Immune Checkpoint Inhibitors Market Size, Share & Trends Analysis.
[2] U.S. Food and Drug Administration. (2010). Biologics Price Competition and Innovation Act.
